Betahistine for Menière's disease or syndrome.

BACKGROUND Menière's disease is characterised by attacks of hearing loss, tinnitus and disabling vertigo. Betahistine is used by many people to reduce the frequency and severity of these attacks but there is conflicting evidence relating to its effects. OBJECTIVES The objective of this review was to assess the effects of betahistine in people with Menière's disease. SEARCH STRATEGY We searched the Cochrane Controlled Trials Register (The Cochrane Library issue 4,1999), MEDLINE (January 1966 to December 1999), EMBASE (January 1985 to December 1999) and Index Medicus (1962 to 1966). We checked reference lists of articles and contacted pharmaceutical companies for further studies. SELECTION CRITERIA Randomised controlled studies of betahistine versus placebo in Menière's disease. DATA COLLECTION AND ANALYSIS Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for further information. MAIN RESULTS Six trials involving 162 patients were included. No trial met the highest quality standard set by the review because of inadequate diagnostic criteria or methods, and none assessed the effect of betahistine on vertigo adequately. Most trials suggested a reduction of vertigo with betahistine and some suggested a reduction in tinnitus but all these effects may have been caused by bias in the methods. One trial with good methods showed no effect of betahistine on tinnitus compared with placebo in 35 patients. None of the trials showed any effect of betahistine on hearing loss. No adverse effects were found with betahistine. REVIEWER'S CONCLUSIONS There is insufficient evidence to say whether betahistine has any effect on Menière's disease.

[1]  B. Fattori,et al.  Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo , 2003, European Archives of Oto-Rhino-Laryngology.

[2]  S. Senn,et al.  Clinical cross-over trials in phase I , 1999, Statistical methods in medical research.

[3]  G. Gates,et al.  Committee on Hearing and Equilibrium Guidelines for the Diagnosis and Evaluation of Therapy in Meniere's Disease ∗ , 1995 .

[4]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[5]  P. Wilson,et al.  Tinnitus reaction questionnaire: psychometric properties of a measure of distress associated with tinnitus. , 1991, Journal of speech and hearing research.

[6]  F K Kuk,et al.  The psychometric properties of a tinnitus handicap questionnaire. , 1990, Ear and hearing.

[7]  E. Smouha,et al.  Natural History vs. Surgery for Meniere's Disease , 1989, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[8]  D. Brackmann,et al.  Committee on Hearing and Equilibrium Guidelines for Reporting Treatment Results in Meniere's Disease , 1985, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[9]  E. D. Meyer,et al.  Zur Behandlung des Morbus Menière mit Betahistindimesilat (Aequamen®) - Doppelblindstudie gegen Plazebo (crossover) , 1985 .

[10]  B. Okafor.  Incidence of Menière's Disease , 1984, The Journal of Laryngology & Otology.

[11]  W. Oosterveld.  Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin A double-blind placebo-controlled study , 1984, The Journal of Laryngology & Otology.

[12]  J. Valentine,et al.  Betahistine in peripheral vertigo , 1981, The Journal of Laryngology & Otology.

[13]  Pedersen Cb,et al.  [Drug information. Therapy in Ménière's disease, with special reference to the use of betahistine, Betaserc]. , 1978 .

[14]  T. Wilmot,et al.  Betahistine in Ménière's disease , 1976, The Journal of Laryngology & Otology.

[15]  I. Frew,et al.  Betahistine hydrochloride in Méniére's disease. , 1976, Postgraduate medical journal.

[16]  A. Yoshida,et al.  [Therapeutic results of betahistine on Meniere's disease. Multi-variable analysis of the results of the double blind test and Fisher's evaluation method]. , 1968, Iryo.

[17]  J. Elia.  Double-blind evaluation of a new treatment for Ménière's syndrome. , 1966, JAMA.

[18]  M. Strauss.  Cecil-Loeb Textbook of Medicine , 1964, The Yale Journal of Biology and Medicine.

[19]  H. L. Williams.  COMMENTS ON MENIERE'S DISEASE. , 1964, Postgraduate medicine.

[20]  C. S. Hallpike,et al.  Observations on the Pathology of Ménière's Syndrome , 1938, The Journal of Laryngology & Otology.

[21]  Igor Sartori,et al.  Empirical Evidence of Bias. Dimensions of Methodological Quality Associated with Estimates of Treatment Effects in Controlled Trials , 1996 .

[22]  H. Timmerman.  Pharmacotherapy of vertigo: any news to be expected? , 1994, Acta oto-laryngologica. Supplementum.

[23]  E. Huizing,et al.  The clinical drug trial in Menière's disease with emphasis on the effect of betahistine SR. , 1992, Acta oto-laryngologica. Supplementum.

[24]  C. Calais,et al.  Vertiges paroxystiques itératifs et SERC: étude clinique contrôlée , 1988 .

[25]  E. D. Meyer.  [Treatment of Meniere disease with betahistine dimesilate (Aequamen)--double-blind study versus placebo (crossover)]. , 1985, Laryngologie, Rhinologie, Otologie.

[26]  A. Svedberg,et al.  The natural course of Meniere's disease. , 1984, Acta oto-laryngologica. Supplementum.

[27]  D. Martinez.  The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. , 1972, Acta oto-laryngologica. Supplementum.

[28]  M. Burton,et al.  Betahistine for Ménière ’ s disease or syndrome ( Review ) , 2022 .